Intravenous Amiodarone Infusion Rate for Rapid Atrial Fibrillation
For rapid atrial fibrillation requiring rate control, administer intravenous amiodarone as 150-300 mg over 1 hour, followed by a continuous infusion of 10-50 mg/hour over 24 hours 1.
Loading and Maintenance Dosing
The 2023 ACC/AHA/ACCP/HRS guidelines provide the definitive dosing regimen 1:
- Initial bolus: 150-300 mg IV over 1 hour
- Maintenance infusion: 10-50 mg/hour continuously over 24 hours
- Total loading dose: 6-10 grams administered over 2-4 weeks (can combine IV and oral dosing to complete)
The FDA label confirms this approach, noting that in clinical trials of VF/VT patients, the regimen consisted of an initial rapid loading infusion, followed by a slower 6-hour loading infusion, then an 18-hour maintenance infusion 2. Peak concentrations after 10-minute infusions of 150 mg range between 7-26 mg/L, with rapid distribution causing serum concentrations to decline to 10% of peak values within 30-45 minutes 2.
Clinical Context and Timing
Amiodarone is generally used for rate control in AF, not as a first-line agent for rapid cardioversion. The guidelines list it under "Other" agents for rate control, distinct from beta-blockers and calcium channel blockers 1. This is important because:
- Most conversions to sinus rhythm occur after 6-8 hours of therapy initiation 3
- Research shows conversion rates of 68-88% by 24 hours, but not significantly better than placebo in some studies 4
- The drug provides effective rate control more rapidly than conversion 5, 6
Important Safety Considerations
Monitor continuously during infusion due to several critical risks:
- Hypotension: Occurs in 16% of patients due to vasodilatory and negative inotropic effects 2
- Bradycardia/asystole: Reported in 1.8% of patients, particularly upon conversion to sinus rhythm 7
- Avoid in heart failure with reduced ejection fraction (HFrEF) when other options are available 1
Contraindication in Preexcited Atrial Fibrillation
Do not use IV amiodarone in Wolff-Parkinson-White syndrome with preexcited AF due to risk of ventricular fibrillation from accelerated conduction down the accessory pathway 8. While recent systematic review data suggest the actual risk may be lower than previously thought (0.12-0.68%), guidelines maintain this as a contraindication 8.
Alternative Dosing Regimens from Research
Higher-dose regimens have been studied but are not guideline-recommended:
- 5 mg/kg over 30 minutes followed by 10 mg/kg over 20 hours showed 83% conversion by 20 hours 7
- 10 mg/kg over 30 minutes in one study 5
- Tailored regimens starting at 5 mg/min for 1 hour, then decreasing stepwise 6
However, stick with the guideline-recommended 150-300 mg over 1 hour followed by 10-50 mg/hour, as this balances efficacy with safety and is the standard of care 1.
Practical Algorithm
- Confirm no contraindications: No WPW with preexcitation, no severe bradycardia
- Establish continuous cardiac monitoring
- Administer loading dose: 150 mg IV over 1 hour (can increase to 300 mg if needed)
- Start maintenance infusion: 10-50 mg/hour for up to 24 hours
- Supplemental boluses: Give additional 150 mg over 10 minutes for breakthrough episodes 2
- Transition to oral: 100-200 mg daily after IV therapy, with loading dose of 6-10 grams over 2-4 weeks 1
The half-life is extremely long (9-36 days IV, 26-107 days oral), so effects persist well beyond infusion cessation 1.